At Cellestial Health, strategic partnerships and collaborations are key to driving our mission forward.
By working with leading institutions and leveraging diverse funding sources, we accelerate the development of innovative therapies for Parkinson’s.
Our collaborative approach enables us to advance cutting-edge research, strengthen our discovery pipeline, and pave the way for the next generation of neurodegenerative disease treatments.
Strategic Support
Cellestial Health has received support from leading organisations including Parkinson’s UK, Cambridge Enterprise, and Zinc VC, to validate our mechanism of action in advanced Parkinson’s models and establish our discovery pipeline. We have ongoing collaborations with the University of Cambridge and the University of Manchester to deepen our translational knowledge of astrocytic networks in Parkinson’s.
Preclinical Expertise
Our collaboration with Charles River Laboratories and o2h discovery brings deep expertise to our preclinical development, further enhancing our strategy. By diversifying our funding through non-dilutive sources and venture capital, we ensure long-term financial stability as we continue advancing our programs.
Future Opportunities
As we progress, we are actively seeking additional funding to further the preclinical development of our lead small molecule asset against the first astrocytic molecular target. We welcome discussions with potential partners and investors who share our vision and are excited by the opportunity to help drive the next breakthrough in Parkinson’s treatment.